ReviewNature reviews. Drug discovery2002
Hepatitis C therapeutics: current status and emerging strategies.
Review in Nature reviews. Drug discovery, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients.Antimicrobial agents and chemotherapy · 2012Trial
- Article
- Prediction of potential NS3-based T cell epitopes of hepatitis C virus by in-silico and in-vitro approach.Scientific reports · 2026Article
- Comparison of the Regulatory Effects of Host Factors on Viral Internal Ribosomal Entry Sites.Veterinary sciences · 2025Article
- Crystal structure and Hirshfeld surface analysis of 4-azido-2-(3,5-di-methyl-phen-yl)-5-(4-nitro-phen-yl)-2Acta crystallographica. Section E, Crystallographic communications · 2023Article
- Study of the Anticancer Potential of Plant Extracts Using Liver Tumor Microphysiological System.Life (Basel, Switzerland) · 2022Article
- Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses.Microorganisms · 2021Article
- A conserved RNA structural motif for organizing topology within picornaviral internal ribosome entry sites.Nature communications · 2019Article
- Synthesis of Carvone-Derived 1,2,3-Triazoles Study of Their Antioxidant Properties and Interaction with Bovine Serum Albumin.Molecules (Basel, Switzerland) · 2018Article
- Article
- Small molecules targeting viral RNA.Wiley interdisciplinary reviews. RNA · 2016Review
- Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.Molecular diversity · 2015Article
- Bioimaging of Hyaluronate-Interferon α Conjugates Using a Non-Interfering Zwitterionic Fluorophore.Biomacromolecules · 2015Article
- Nanostructures for the Inhibition of Viral Infections.Molecules (Basel, Switzerland) · 2015Review
- Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis.Experimental and therapeutic medicine · 2015Article
- Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases.World journal of gastroenterology · 2014Review
- 3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C.World journal of gastroenterology · 2014Article
- Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden.Infection ecology & epidemiology · 2014Article
- Evidence for novel hepaciviruses in rodents.PLoS pathogens · 2013Article
- HCV IRES-mediated core expression in zebrafish.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic infection with hepatitis C virus (HCV) is an emerging global epidemic. The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus. Despite these obstacles, inhibitors of the replicative elements of HCV, immune modulators and non-specific hepatoprotective agents are being pursued and exciting progress has been made. Successful therapeutic intervention of HCV will probably require combination approaches and new approaches, including host drug discovery targets.
Indexed as
Identifiers
12415247What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.